Send to

Choose Destination
Med Microbiol Immunol. 2008 Jun;197(2):97-107. doi: 10.1007/s00430-008-0085-2. Epub 2008 Mar 5.

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Author information

Institute for Virology, Johannes Gutenberg-Universität, Obere Zahlbacher Str. 67, 55101 Mainz, Germany.


Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now. Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined. Analysis of viral mutants that were constructed in this process provided the proof-of-principle that heterologous antigens can be packaged into recDB and that these particles prime CD8 T cell responses against the recombinant antigen upon their application to HLA-A2 transgenic mice.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center